» Articles » PMID: 23756783

Increased Carotid Intima Media Thickness is Associated with Prolactin Levels in Subjects with Untreated Prolactinoma: a Pilot Study

Overview
Journal Pituitary
Specialty Endocrinology
Date 2013 Jun 13
PMID 23756783
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperprolactinemia is associated with endothelial dysfunction and atherogenic risk factors, but carotid intima media thickness (IMT) has not been studied in hyperprolactinemic patients. To determine whether untreated hyperprolactinemia contributes to increased carotid IMT. Thirty-one prolactinoma patients and 60 healthy controls were respectively studied. Participants underwent hormone evaluation. Anthropometric parameters (body mass index and blood pressure), inflammatory markers (high-sensitivity C-reactive protein and fibrinogen), serum glucose, insulin, lipid and apolipoprotein profiles were also determined. Endothelial function measured as the flow-mediated dilation (FMD) of a brachial artery and carotid IMT were evaluated using high-resolution ultrasonography. Multivariate linear regression analysis was applied to identify independent determinants of FMD and carotid IMT. Triglycerides, homeostasis model assessment of insulin resistance, apolipoprotein (apo)B/apoA-I ratio, high-sensitivity C-reactive protein (hsCRP) and fibrinogen were significantly higher, while apoA-I was significantly lower in patients with prolactinomas than in the controls. Meanwhile, decreased FMD and increased carotid IMT were observed in hyperprolactinemic group. Serum prolactin was positively correlated with triglycerides, apoB/apoA-I ratio, hypogonadal, hsCRP and fibrinogen (P < 0.05), but inversely associated with apoA-I and HDL-C (P ≤ 0.001). Moreover, prolactin was found negatively correlated with FMD (r = -0.576, P < 0.0001), and positively correlated with mean carotid IMT (r = 0.652, P < 0.0001). Multivariate regression analysis revealed that prolactin determined, independent of traditional risk factors, FMD (B = -0.589, 95% confidence interval (CI) -2.525 to -0.804, P = 0.001) and mean carotid IMT (B = 0.527, 95% CI 0.027-0.069, P < 0.0001). Hyperprolactinemia may be involved in the preclinical increase in carotid IMT, directly or by promoting atherogenic factors, including insulin resistance, low-grade inflammation and endothelial dysfunction. Additional studies are warranted to confirm our findings and explore the mechanisms underlying prolactin-associated early atherosclerosis.

Citing Articles

The Influence of Concurrent Autoimmune Thyroiditis on the Cardiometabolic Consequences of Cabergoline in Postmenopausal Women.

Krysiak R, Basiak M, Szkrobka W, Okopien B Metabolites. 2025; 15(1).

PMID: 39852352 PMC: 11767027. DOI: 10.3390/metabo15010009.


Mildly elevated serum prolactin level may be a protective factor for preventing thickening of the carotid intima-media in patients with type 2 diabetes mellitus.

Zhang B, Ke J, Zhang N, Zhao W, Zhong L Endocr Connect. 2024; 14(1.

PMID: 39526908 PMC: 11728874. DOI: 10.1530/EC-24-0285.


An Overview of Cardiovascular Risk in Pituitary Disorders.

Ntali G, Markussis V, Chrisoulidou A Medicina (Kaunas). 2024; 60(8).

PMID: 39202522 PMC: 11356746. DOI: 10.3390/medicina60081241.


Muscle function, exercise capacity, physical activity level and cardiovascular disease risk factor knowledge in patients with prolactinoma.

Erkoc A, Eroglu I, Erbas T, Calik Kutukcu E Endocrine. 2024; 85(3):1337-1345.

PMID: 38801597 DOI: 10.1007/s12020-024-03880-7.


Metabolic Abnormalities, Inflammatory Markers and Endothelial Dysfunction in Hyperprolactinemia due to Prolactinoma before and after Normalization of Serum Prolactin: A Prospective Case Control Study.

Baba M, Laway B, Misgar R, Wani A, Bashir M, Bhat I Indian J Endocrinol Metab. 2023; 27(4):357-364.

PMID: 37867992 PMC: 10586551. DOI: 10.4103/ijem.ijem_201_22.


References
1.
Skipworth R, Moses A, Sangster K, Sturgeon C, Voss A, Fallon M . Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 2010; 19(3):391-401. DOI: 10.1007/s00520-010-0832-y. View

2.
de Assuncao Alves Rodrigues L, Campos S, Miranda P, Bizzi M, Sales do Amaral P, Giannetti A . Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012; 44(11):832-8. DOI: 10.1055/s-0032-1321832. View

3.
Daly A, Rixhon M, Adam C, Dempegioti A, Tichomirowa M, Beckers A . High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006; 91(12):4769-75. DOI: 10.1210/jc.2006-1668. View

4.
Montes de Oca P, Macotela Y, Nava G, Lopez-Barrera F, Martinez de la Escalera G, Clapp C . Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest. 2005; 85(5):633-42. DOI: 10.1038/labinvest.3700256. View

5.
Reuwer A, van Eijk M, Houttuijn-Bloemendaal F, van der Loos C, Claessen N, Teeling P . The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis?. J Endocrinol. 2010; 208(2):107-17. DOI: 10.1677/JOE-10-0076. View